Trials / Completed
CompletedNCT03266588
Open Label Safety Study in Acute Treatment of Migraine
A Multicenter, Open Label Long-Term Safety Study of BHV-3000 in the Acute Treatment of Migraine
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 3,019 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate safety and tolerability of BHV-3000 (rimegepant).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rimegepant | 75 mg oral tablet |
Timeline
- Start date
- 2017-08-30
- Primary completion
- 2019-07-15
- Completion
- 2019-07-15
- First posted
- 2017-08-30
- Last updated
- 2023-02-16
- Results posted
- 2020-07-02
Locations
98 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03266588. Inclusion in this directory is not an endorsement.